Clinical Trial Update: Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions [Phase 2]

View source ↗

Summary

Phase 2 study evaluating cetuximab plus irinotecan in advanced colorectal cancer with wild-type KRAS, irrespective of EGFR expression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Asan Medical Center | Conditions: Advanced Colorectal Cancer | Phase 2 | Status: COMPLETED